Highlighted as game changer in drug development & delivery special feature on innovative technologies for improving drug solubility and bioavailability
Under the terms of the agreement, Vipergen will apply its in-living-cell DNA-encoded library (DEL) screening platform to discover novel small-molecule compounds that bind to a selected Theseus kinase target
Sanofi’s DE&I Board will include three of the most influential voices in the DE&I space as Board members appointed for 3 years: organizational psychologist & best-selling author John Amaechi, award-winning social entrepreneur Caroline Casey, and DE&I pioneer and renowned thought-leader Dr. Rohini Anand
There is also a strong synergy between Jubilant and Greencure with respect to OTC portfolio which can be explored for R&D, online acceleration and offline distribution
Through this consortium, Lonza will collaborate with other industry leaders to advance the research and development of inhalation technologies
The event will have a mix of policymakers, national and international leaders from the pharma industry, MSME, innovators, academic and research fraternity
It is an application to automate statistical analysis and reporting for clinical research.
Vortioxetine is a novel antidepressant with multimodal activity, which is approved to treat Major Depressive Disorder (MDD) in adults
The amalgamation will integrate business operations and provide impetus to the existing portfolio of Alembic
It celebrated its 100th session as LPC-100 in association with Mundial Pharma
Subscribe To Our Newsletter & Stay Updated
